Roche cobas 4800 | ||||
---|---|---|---|---|
Negative | Positive | Agreement (%) | kappaa | |
ChapterDx HPV-STI NGS assay | ||||
Overall agreement | ||||
Negative | 26 | 0 | 97.5 | 0.867 (95% CI 0.771–0.963) |
Positive | 7 | 241 | ||
NLM (102) | ||||
Negative | 17 | 0 | 95.1 | 0.842 (95% CI 0.709–0.975) |
Positive | 5 | 80 | ||
LSIL (101) | ||||
Negative | 7 | 0 | 98 | 0.864 (95% CI 0.680–1) |
Positive | 2 | 92 | ||
HSIL (57) | ||||
Negative | 0 | 0 | 100 | 1 |
Positive | 0 | 57 | ||
CIN1 (4) | ||||
Negative | 0 | 0 | 100 | 1 |
Positive | 0 | 4 | ||
CIN2/3 (59) | ||||
Negative | 0 | 0 | 100 | 1 |
Positive | 0 | 59 | ||
Squamous carcinomab (3) | ||||
Negative | 1 | 0 | 100 | 1 |
Positive | 0 | 2 | ||
Adenocarcinomac (2) | ||||
Negative | 1 | 0 | 100 | 1 |
Positive | 0 | 1 |